Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Nomura Holdings Inc (NMR) Price & Performance

ADMA Biologics IncTrade
Nomura Holdings IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Nomura Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.83 (market cap $2.22B), while Nomura Holdings Inc trades at $9.93 (market cap $28.46B). The key difference: Nomura Holdings Inc is far larger — about 12.8× ADMA Biologics Inc's market cap, and Nomura Holdings Inc pays a 3.31% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMANMR
Market Cap
$2.22B$28.46B
Sector
HealthFinancials
52-Week High
$20.38$10.04
52-Week Low
$7.60$6.73
Enterprise Value
$2.29B
Dividend Yield
3.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.

The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.

Nomura Holdings Inc

Nomura Holdings (NMR) trades at $9.905, up 0.87% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.59, net income margin of 20.4%, and robust revenue growth to $1.66 trillion in 2025. Recent Q2 2026 earnings beat expectations, and news highlights momentum in wholesale and wealth management divisions.

Outlook remains positive due to earnings strength and undervaluation, but risks include volatile cash flows and rising debt-to-asset ratio. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism amid operational challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Nomura Holdings Inc

Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.

Read more on NMR